iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021

NEXT STORY
TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting
PREV STORY
Immunoassay Market Worth $46.5 Billion by 2028, Growing at a CAGR of 7.5% From 2021- Exclusive Report by Meticulous Research®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Nasal Cannula Market size worth $ 9.54 Billion, Globally, by 2028 at 5.12% CAGR: Verified Market Research™

author_avatar
NASDAQ Market News

Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis

author_avatar
NASDAQ Market News

Curetis Expands Supervisory and Medical Advisory Boards

Curetis Expands Supervisory and Medical Advisory Boards - Dr. Nils Clausnitzer nominated for election ...

author_avatar
NASDAQ Market News